Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity

Journal of Proteome Research

Volumn 15, Issue 2, 2016, Pages 667-676

  Barthélemy, Nicolas R ^a,b   Fenaille, François ^a   Hirtz, Christophe ^b   Sergeant, Nicolas ^c   Schraen Maschke, Susanna ^c   Vialaret, Jérôme ^b   Buée, Luc ^c   Gabelle, Audrey ^b,d   Junot, Christophe ^a   Lehmann, Sylvain ^b   Becher, François ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b HÔPITAL SAINT ELOI   (France)

^c UNIV LILLE   (France)

^d GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

alternative splicing dependent peptides; cerebrospinal fluid; microtubule associated tau protein; parallel reaction monitoring; protein absolute quantification; protein fragments; protein precipitation; solid phase extraction

Indexed keywords

TAU PROTEIN; BIOLOGICAL MARKER; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; CHEMISTRY; DEVICES; MOLECULAR GENETICS; PROCEDURES; REPRODUCIBILITY;

AMINO ACID SEQUENCE; BIOMARKERS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDES; REPRODUCIBILITY OF RESULTS; TAU PROTEINS;

EID: 84957625003     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/acs.jproteome.5b01001     Document Type: Article

References (43)

1. Sergeant, N.; Bretteville, A.; Hamdane, M.; Caillet-Boudin, M. L.; Grognet, P.; Bombois, S.; Blum, D.; Delacourte, A.; Pasquier, F.; Vanmechelen, E.; Schraen-Maschke, S.; Buee, L. Biochemistry of Tau in Alzheimer's disease and related neurological disorders Expert Rev. Proteomics 2008, 5, 207-224 10.1586/14789450.5.2.207
2. Sanders, D. W.; Kaufman, S. K.; DeVos, S. L.; Sharma, A. M.; Mirbaha, H.; Li, A.; Barker, S. J.; Foley, A. C.; Thorpe, J. R.; Serpell, L. C.; Miller, T. M.; Grinberg, L. T.; Seeley, W. W.; Diamond, M. I. Distinct tau prion strains propagate in cells and mice and define different tauopathies Neuron 2014, 82, 1271-1288 10.1016/j.neuron.2014.04.047
3. Dujardin, S.; Lecolle, K.; Caillierez, R.; Begard, S.; Zommer, N.; Lachaud, C.; Carrier, S.; Dufour, N.; Auregan, G.; Winderickx, J.; Hantraye, P.; Deglon, N.; Colin, M.; Buee, L. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies Acta Neuropathol. Commun. 2014, 2, 14 10.1186/2051-5960-2-14
4. Iqbal, K.; Liu, F.; Gong, C. X.; Grundke-Iqbal, I. Tau in Alzheimer disease and related tauopathies Curr. Alzheimer Res. 2010, 7, 656-664 10.2174/156720510793611592
5. Hanger, D. P.; Lau, D. H.; Phillips, E. C.; Bondulich, M. K.; Guo, T.; Woodward, B. W.; Pooler, A. M.; Noble, W. Intracellular and extracellular roles for tau in neurodegenerative disease J. Alzheimers Dis. 2014, 40 (Suppl 1) S37-S45
6. Thomas, S. N.; Funk, K. E.; Wan, Y.; Liao, Z.; Davies, P.; Kuret, J.; Yang, A. J. Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach Acta Neuropathol. 2012, 123, 105-117 10.1007/s00401-011-0893-0
7. Morris, M.; Knudsen, G. M.; Maeda, S.; Trinidad, J. C.; Ioanoviciu, A.; Burlingame, A. L.; Mucke, L. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice Nat. Neurosci. 2015, 18, 1183-1189 10.1038/nn.4067
8. Sergeant, N.; Wattez, A.; Delacourte, A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms J. Neurochem. 1999, 72, 1243-1249 10.1046/j.1471-4159.1999.0721243.x
9. Clark, L. N.; Poorkaj, P.; Wszolek, Z.; Geschwind, D. H.; Nasreddine, Z. S.; Miller, B.; Li, D.; Payami, H.; Awert, F.; Markopoulou, K.; Andreadis, A.; D'Souza, I.; Lee, V. M.; Reed, L.; Trojanowski, J. Q.; Zhukareva, V.; Bird, T.; Schellenberg, G.; Wilhelmsen, K. C. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17 Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 13103-13107 10.1073/pnas.95.22.13103
10. Buee, L.; Bussiere, T.; Buee-Scherrer, V.; Delacourte, A.; Hof, P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders Brain Res. Rev. 2000, 33, 95-130 10.1016/S0165-0173(00)00019-9
11. Savaryn, J. P.; Catherman, A. D.; Thomas, P. M.; Abecassis, M. M.; Kelleher, N. L. The emergence of top-down proteomics in clinical research Genome Med. 2013, 5, 53 10.1186/gm457
12. Kanmert, D.; Cantlon, A.; Muratore, C. R.; Jin, M.; O'Malley, T. T.; Lee, G.; Young-Pearse, T. L.; Selkoe, D. J.; Walsh, D. M. C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death J. Neurosci. 2015, 35, 10851-10865 10.1523/JNEUROSCI.0387-15.2015
13. Derisbourg, M.; Leghay, C.; Chiappetta, G.; Fernandez-Gomez, F. J.; Laurent, C.; Demeyer, D.; Carrier, S.; Buee-Scherrer, V.; Blum, D.; Vinh, J.; Sergeant, N.; Verdier, Y.; Buee, L.; Hamdane, M. Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms Sci. Rep. 2015, 5, 9659 10.1038/srep09659
14. Wagshal, D.; Sankaranarayanan, S.; Guss, V.; Hall, T.; Berisha, F.; Lobach, I.; Karydas, A.; Voltarelli, L.; Scherling, C.; Heuer, H.; Tartaglia, M. C.; Miller, Z.; Coppola, G.; Ahlijanian, M.; Soares, H.; Kramer, J. H.; Rabinovici, G. D.; Rosen, H. J.; Miller, B. L.; Meredith, J.; Boxer, A. L. Divergent CSF tau alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy J. Neurol., Neurosurg. Psychiatry 2015, 86, 244-250 10.1136/jnnp-2014-308004
15. Blennow, K.; Wallin, A.; Agren, H.; Spenger, C.; Siegfried, J.; Vanmechelen, E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 1995, 26, 231-245 10.1007/BF02815140
16. Otto, M.; Wiltfang, J.; Tumani, H.; Zerr, I.; Lantsch, M.; Kornhuber, J.; Weber, T.; Kretzschmar, H. A.; Poser, S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurosci. Lett. 1997, 225, 210-212 10.1016/S0304-3940(97)00215-2
17. Kuiperij, H. B.; Verbeek, M. M. Detection of tau forms in CSF requires sensitive techniques Neurobiol. Aging 2012, 33, 1841 10.1016/j.neurobiolaging.2011.03.013
18. Meredith, J. E., Jr.; Sankaranarayanan, S.; Guss, V.; Lanzetti, A. J.; Berisha, F.; Neely, R. J.; Slemmon, J. R.; Portelius, E.; Zetterberg, H.; Blennow, K.; Soares, H.; Ahlijanian, M.; Albright, C. F. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease PLoS One 2013, 8, e76523 10.1371/journal.pone.0076523
19. Portelius, E.; Hansson, S. F.; Tran, A. J.; Zetterberg, H.; Grognet, P.; Vanmechelen, E.; Hoglund, K.; Brinkmalm, G.; Westman-Brinkmalm, A.; Nordhoff, E.; Blennow, K.; Gobom, J. Characterization of tau in cerebrospinal fluid using mass spectrometry J. Proteome Res. 2008, 7, 2114-2120 10.1021/pr7008669
20. Peterson, A. C.; Russell, J. D.; Bailey, D. J.; Westphall, M. S.; Coon, J. J. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics Mol. Cell. Proteomics 2012, 11, 1475-1488 10.1074/mcp.O112.020131
21. Gallien, S.; Duriez, E.; Crone, C.; Kellmann, M.; Moehring, T.; Domon, B. Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer Mol. Cell. Proteomics 2012, 11, 1709-1723 10.1074/mcp.O112.019802
22. Jaquinod, M.; Trauchessec, M.; Huillet, C.; Louwagie, M.; Lebert, D.; Picard, G.; Adrait, A.; Dupuis, A.; Garin, J.; Brun, V.; Bruley, C. Mass spectrometry-based absolute protein quantification: PSAQ strategy makes use of "noncanonical" proteotypic peptides Proteomics 2012, 12, 1217-1221 10.1002/pmic.201100538
23. Picard, G.; Lebert, D.; Louwagie, M.; Adrait, A.; Huillet, C.; Vandenesch, F.; Bruley, C.; Garin, J.; Jaquinod, M.; Brun, V. PSAQ standards for accurate MS-based quantification of proteins: from the concept to biomedical applications J. Mass Spectrom. 2012, 47, 1353-1363 10.1002/jms.3106
24. Brun, V.; Dupuis, A.; Adrait, A.; Marcellin, M.; Thomas, D.; Court, M.; Vandenesch, F.; Garin, J. Isotope-labeled protein standards: toward absolute quantitative proteomics Mol. Cell. Proteomics 2007, 6, 2139-2149 10.1074/mcp.M700163-MCP200
25. Lippens, G.; Wieruszeski, J. M.; Leroy, A.; Smet, C.; Sillen, A.; Buee, L.; Landrieu, I. Proline-directed random-coil chemical shift values as a tool for the NMR assignment of the tau phosphorylation sites ChemBioChem 2004, 5, 73-78 10.1002/cbic.200300763
26. Huttenhain, R.; Soste, M.; Selevsek, N.; Rost, H.; Sethi, A.; Carapito, C.; Farrah, T.; Deutsch, E. W.; Kusebauch, U.; Moritz, R. L.; Nimeus-Malmstrom, E.; Rinner, O.; Aebersold, R. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics Sci. Transl. Med. 2012, 4, 142ra94 10.1126/scitranslmed.3003989
27. Stergachis, A. B.; MacLean, B.; Lee, K.; Stamatoyannopoulos, J. A.; MacCoss, M. J. Rapid empirical discovery of optimal peptides for targeted proteomics Nat. Methods 2011, 8, 1041-1043 10.1038/nmeth.1770
28. Proc, J. L.; Kuzyk, M. A.; Hardie, D. B.; Yang, J.; Smith, D. S.; Jackson, A. M.; Parker, C. E.; Borchers, C. H. A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin J. Proteome Res. 2010, 9, 5422-5437 10.1021/pr100656u
29. Brownridge, P.; Beynon, R. J. The importance of the digest: proteolysis and absolute quantification in proteomics Methods 2011, 54, 351-360 10.1016/j.ymeth.2011.05.005
30. Rodriguez, J.; Gupta, N.; Smith, R. D.; Pevzner, P. A. Does trypsin cut before proline? J. Proteome Res. 2008, 7, 300-305 10.1021/pr0705035
31. Fortin, T.; Salvador, A.; Charrier, J. P.; Lenz, C.; Lacoux, X.; Morla, A.; Choquet-Kastylevsky, G.; Lemoine, J. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests Mol. Cell. Proteomics 2009, 8, 1006-1015 10.1074/mcp.M800238-MCP200
32. Percy, A. J.; Chambers, A. G.; Yang, J.; Hardie, D. B.; Borchers, C. H. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility Biochim. Biophys. Acta, Proteins Proteomics 2014, 1844, 917-926 10.1016/j.bbapap.2013.06.008
33. Gallien, S.; Duriez, E.; Demeure, K.; Domon, B. Selectivity of LC-MS/MS analysis: implication for proteomics experiments J. Proteomics 2013, 81, 148-158 10.1016/j.jprot.2012.11.005
34. Gabelle, A.; Dumurgier, J.; Vercruysse, O.; Paquet, C.; Bombois, S.; Laplanche, J. L.; Peoc'h, K.; Schraen, S.; Buee, L.; Pasquier, F.; Hugon, J.; Touchon, J.; Lehmann, S. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study J. Alzheimers Dis. 2013, 34, 297-305 10.3233/JAD-121549
35. McAvoy, T.; Lassman, M. E.; Spellman, D. S.; Ke, Z.; Howell, B. J.; Wong, O.; Zhu, L.; Tanen, M.; Struyk, A.; Laterza, O. F. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry Clin. Chem. 2014, 60, 683-689 10.1373/clinchem.2013.216515
36. Lame, M. E.; Chambers, E. E.; Blatnik, M. Quantitation of amyloid beta peptides Abeta(1-38), Abeta(1-40), and Abeta(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry Anal. Biochem. 2011, 419, 133-139 10.1016/j.ab.2011.08.010
37. Lindwall, G.; Cole, R. D. The purification of tau protein and the occurrence of two phosphorylation states of tau in brain J. Biol. Chem. 1984, 259, 12241-12245
38. Simon, R.; Girod, M.; Fonbonne, C.; Salvador, A.; Clement, Y.; Lanteri, P.; Amouyel, P.; Lambert, J. C.; Lemoine, J. Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n = 669): a pilot assay for methionine-containing proteotypic peptides Mol. Cell. Proteomics 2012, 11, 1389-1403 10.1074/mcp.M112.018861
39. Pesavento, J. J.; Garcia, B. A.; Streeky, J. A.; Kelleher, N. L.; Mizzen, C. A. Mild performic acid oxidation enhances chromatographic and top down mass spectrometric analyses of histones Mol. Cell. Proteomics 2007, 6, 1510-1526 10.1074/mcp.M600404-MCP200
40. Zemlan, F. P.; Rosenberg, W. S.; Luebbe, P. A.; Campbell, T. A.; Dean, G. E.; Weiner, N. E.; Cohen, J. A.; Rudick, R. A.; Woo, D. Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins J. Neurochem. 1999, 72, 741-750 10.1046/j.1471-4159.1999.0720741.x
41. Kang, J. H.; Korecka, M.; Toledo, J. B.; Trojanowski, J. Q.; Shaw, L. M. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers Clin. Chem. 2013, 59, 903-916 10.1373/clinchem.2013.202937
42. Olsson, A.; Vanderstichele, H.; Andreasen, N.; De, M. G.; Wallin, A.; Holmberg, B.; Rosengren, L.; Vanmechelen, E.; Blennow, K. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology Clin. Chem. 2005, 51, 336-345 10.1373/clinchem.2004.039347
43. Bros, P.; Vialaret, J.; Barthelemy, N.; Delatour, V.; Gabelle, A.; Lehmann, S.; Hirtz, C. Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry Front. Neurosci. 2015, 9, 302-310 10.3389/fnins.2015.00302